XERIS BIOPHARMA HOLDINGS, INC. Consolidated Statements of Stockholders’ Equity (in thousands, except share data) Common Stock Additional Paid In Capital Accumulated Other Comprehensive Income (Loss) Accumulated Deficit Total Stockholders' Equity Shares Amount Balance, December 31, 2019 27,214,523 $ 3 $ 260,635 $ 43 $ (246,245) $ 14,436 Net loss — — — — (91,140) (91,140) Issuance of common stock upon equity offering 18,809,769 2 61,512 — — 61,514 Issuance of common stock upon conversion of convertible notes 13,171,791 1 39,936 — — 39,937 Exercise of stock options 100,866 — 172 — — 172 Vesting of restricted stock units and related repurchases 21,449 — (63) — — (63) Stock-based compensation — — 8,273 — — 8,273 Issuance of common stock through employee stock purchase plan 292,804 — 669 — — 669 Other comprehensive income — — — (37) — (37) Balance, December 31, 2020 59,611,202 $ 6 $ 371,134 $ 6 $ (337,385) $ 33,761 Net loss — — — — (122,725) (122,725) Issuance of common stock upon equity offering 6,553,398 1 26,924 — — 26,925 Issuance of common stock in connection with the Transactions 58,082,606 6 137,649 — — 137,655 Issuance of equity awards to Strongbridge equity award holders in connection with the Transactions — — 7,964 — — 7,964 Exercise of stock options 93,399 — 199 — — 199 Vesting of restricted stock units and related repurchases 316,772 — (534) — — (534) Stock-based compensation — — 11,381 — — 11,381 Issuance of common stock through employee stock purchase plan 215,939 — 642 — — 642 Other comprehensive loss — — — (37) — (37) Balance, December 31, 2021 124,873,316 $ 13 $ 555,359 $ (31) $ (460,110) $ 95,231 See accompanying notes to consolidated financial statements. 92
RkJQdWJsaXNoZXIy NTIzOTM0